Earnings Summary

NovoCure Limited’s revenue fell -11.17% since last year same period to $122.18Mn in the Q1 2023. On a quarterly growth basis, NovoCure Limited has generated -4.86% fall in its revenue since last 3-months.

NovoCure Limited’s net profit fell -1041.83% since last year same period to $-53.06Mn in the Q1 2023. On a quarterly growth basis, NovoCure Limited has generated -42.24% fall in its net profits since last 3-months.

NovoCure Limited’s net profit margin fell -1185.42% since last year same period to -43.43% in the Q1 2023. On a quarterly growth basis, NovoCure Limited has generated -49.52% fall in its net profit margins since last 3-months.

NovoCure Limited’s earning per share (EPS) estimates for the current quarter stand at -0.36 - a -52.13% fall from last quarter’s estimates.

NovoCure Limited’s earning per share (EPS) estimates for the current year stand at -0.36.

NovoCure Limited’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q2 2023. This indicates that the NovoCure Limited has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.